Acquired Hemophilia A Post-COVID-19 Vaccination: A Case Report ...



trisomy down syndrome :: Article Creator

Trisomy 21 Causes Down Syndrome

One could argue that the presence of extra copies of chromosome 21 in DS patients is only a correlation between an abnormality and the disease. However, scientists have developed trisomic mouse models that display symptoms of human DS, providing strong evidence that extra copies of chromosome 21 are, indeed, responsible for DS. It is possible to construct mouse models of DS because mouse chromosomes contain several regions that are syntenic with regions on human chromosome 21. (Syntenic regions are chromosomal regions in two different species that contain the same linear order of genes.) With mapping of the human and mouse genomes now complete, researchers can identify syntenic regions in mouse and human chromosomes with great precision.

As shown in Figure 4, regions on the arms of mouse chromosomes 10 (MMU10), 16 (MMU16), and 17 (MMU17) are syntenic with regions on the long q arm of human chromosome 21. Using some genetic tricks, scientists have induced translocations involving these mouse chromosomes, producing mice that are trisomic for regions suspected to play a role in DS. (Note that these are not perfect models, because the trisomic regions contain many mouse genes in addition to those that are syntenic to human chromosome 21 genes.) These experiments have shown that genes from MMU16 are probably most important in DS, because mice carrying translocations from MMU16 display symptoms more like human DS than mice carrying translocations of MMU10 or MMU17.

Additional experiments have tried to identify particularly important genes within this region by transferring smaller segments of the interval on MMU16. For example, the three mouse models depicted on the right in Figure 4 carry different portions of MMU16, and all display some symptoms of DS. Of the three, the most faithful model of DS is the Ts65Dn mouse, which carries 132 genes that are syntenic with human chromosome 21. This particular mouse demonstrates many of the symptoms of human DS, including altered facial characteristics, memory and learning problems, and age-related changes in the forebrain.

These results are both daunting and promising. On one hand, they suggest that there will be no magic bullet for treating DS, because large numbers of genes are most likely involved in the condition. On the other hand, the results suggest that mouse models will be useful in developing treatments for the many DS patients around the world.

Figure 4: Regions of synteny between human chromosome 21 (HSA21) and mouse chromosomes (MMUs) 16, 17, and 10.

There are three partial trisomy mouse models of human trisomy 21, all trisomic for a portion of MMU 16. The gene content of these partial trisomies is shown on the right.


Down Syndrome Market Size, With Industry Share, Growth, Trends Analysis By 2031

Report Ocean recently released a research report on the Down Syndrome Market, which covers the market's historical growth, cost structure, revenue, trends, and potential prospects for the period 2023-2031. The report provides an extensive coverage of the market across various categories and includes a detailed analysis at the national level, along with an evaluation of the key drivers, restraints, trends, and opportunities in the market.

The global down syndrome market is expected to reach US$ 3,775.8 Million by 2030. The market is expected to experience the growth rate of 17.3% from 2021 to 2030.

Request To Download Sample of This Strategic Report @https://reportocean.Com/industry-verticals/sample-request?Report_id=Pol578

Increase in the awareness, new technologies and governmental support marks the hike in the global Down Syndrome market and makes it demanding. Down syndrome affects about 1 in 700 newborn babies. About 5,300 babies with Down syndrome are born in the United States each year, and approximately 200,000 people in USA have the condition. Although women of any age can have a child with Down syndrome, the chance of having a child with Down Syndrome increases in older women, though the men still remain infertile.

Down Syndrome also called Trisomy 21, is a chromosomal disorder which is the result of incorrect cell-division or an extra cell division. The abnormal cell division causes a gain of extra full or partial copy of chromosome number 21 causing a lot of mental and physical disabilities in the child. Some of the physical developmental changes occur in the child are - flattened face, small neck & head, poor muscle tone, short in height, excessive flexibility, almond-shaped eyes pointing upwards, short fingers with a single crease in the hand, obesity and small ears that are usually unshaped. All the infected patients are mentally slow but the frequencies differ in different patients. Mental disabilities include slow learning disabilities and lack of problem-solving abilities Sometimes the behavior differs because of the different environments they grow up. Down Syndrome children grow at a slower rate, their speech and language develop later and more slowly than in children without Down syndrome. Down Syndrome children often show behavioral issues such as not paying attention, compulsive behavior, and stubbornness or tantrums.

There are specialized clinics and hospitals available for Down Syndrome patients, and the special medications enhance in the global Down Syndrome market growth. Down Syndrome cannot be permanently cured although the infected child doesn't have any kind of serious illness other than slow mental abilities.

Market Dynamics

The increasing prevalence of Down syndrome, rise in awareness about this condition, availability of specialized hospitals and personal care clinics a governmental support are the major drivers that propel the growth of the global Down syndrome market. Increase in awareness about Down syndrome has allowed people to opt for advanced therapies and novel diagnostic approaches. In addition, technological advancements and increase of government support for R&D activities focused on treatment therapies for Down syndrome contribute as drivers for the global Down Syndrome market growth. Medicinal treatment and drug therapies are currently not seen as an option for the treatment of Down Syndrome. Crucial drugs like Diuretics and digoxin are used in congenital heart defects in Down Syndrome children. The Down Syndrome Association of NSW (New South Wales) was established in 1980 by parents of young people with Down syndrome, this association is one of the key factors which spread awareness about the syndrome when people were not aware. In April 2017, Illumina, Inc. Launched Veri Seq NIPT solution in Europe. The product launched is a CE-IVD marked next-generation sequencing technology-based approach used for screening of chromosomal abnormalities and proved a big help for providing accurate information about chromosomal abnormalities.

Download Sample Report, SPECIAL OFFER (Avail an Up-to 30% discount on this report ) @https://reportocean.Com/industry-verticals/sample-request?Report_id=Pol578

The major restraint in the global Down Syndrome market is that it there are no medicine-based treatments available yet. Unawareness still prevails and recent surveys in the U.S. Of parents, doctors, and medical students indicate that outdated and inaccurate information about Down syndrome is being provided to pregnant women who are prenatally diagnosed or at birth of their child. There is a major lack of funding for research benefitting people with Down syndrome, even compared to other conditions and diseases. Without research funding, best practices in terms of how people with Down syndrome learn in a classroom cannot be studied nor tools created for teachers and parents.

The U.S. Dominates the global Down Syndrome Market and as a large number of Down Syndrome patients are seen in the U.S. And it is marking its foots and impact on almost all the developed countries which marks the boost in the global Down Syndrome Market.

Down Syndrome has been recognized as a clinical entity for about 150 years, but recently there has been a hope for the possibility to understand its pathogenesis and to use this information to devise approaches for the prevention and treatment of its numerous features. The earlier pessimism was due to several reasons, including the nature of the genetic defect that leads to the syndrome, the multiplicity of systems involved, and the high degree of variability of the phenotype. However, science has now caught up with the problem, and come up with the developments, marking boost in the global Down Syndrome Market.

Market Segmentation

The global Down Syndrome market is usually segmented on the basis of - disease type, test type, end user and distribution channel. On the basis of disease type, the global Down Syndrome market is segmented into trisomy 21, translocation Down syndrome and mosaic Down syndrome. Trisomy 21 segment is dominating the market as most of the cases of Down Syndrome are trisomy 21. On the basis of treatment, the global Down syndrome market is segmented into diagnosis and therapy. In 0000, diagnosis segment is dominating the market as most of the parents undertake prenatal tests to understand the condition of the fetus. On the basis of end user, the global Down syndrome market is segmented into hospital, clinics, homecare setting, therapy centers and others. In 0000, hospital segment is dominating the market because they are the primary establishments for prenatal testing. On the basis of distribution channel, the Down syndrome market is segmented into direct tender, retail sales and others. Direct tender segment is dominating in the market as it is the primary mode of purchase of diagnostic products by hospitals and clinics.

Get The Insights You Need By Customizing Your Report To Fit Your Unique Needs And Goals:https://reportocean.Com/industry-verticals/sample-request?Report_id=Pol578

Geography Analysis

Based on the region, the global Down Syndrome market is segmented into U.S., North America, Asia Pacific, Europe, Latin America, The Middle East and Africa. The United States accounts for the highest market size of Down syndrome Kingdom. For instance, in April 2017, VeriSeq NIPT solution was launched by Illumina, Inc. In Europe. This product is a CE-IVD market sequencing technology-based approach. It is used for screening chromosomal abnormalities and can provide the chromosomal status in just 10 weeks of gestation.

The prominent players in the global Down Syndrome Market are Illumina Inc., AC Immune SA, Aelis Pharma SAS, Alzheon Inc., Annovis Bio Inc., Avanti Biosciences Inc, Balance Therapeutics Inc., Eisai Co Ltd., Elixirgen Therapeutics LLC, F. Hoffmann-La Roche Ltd, Kino Pharma Inc., ManRos Therapeutics, NeuroCircuit Therapeutics Inc., NeuroNascent Inc.

Table of Content

Chapter 1: Global Down Syndrome Industry Overview

Chapter 3: Market Dynamics

Chapter 4: Top Company Profiles

Chapter 5: Global Down Syndrome market Competition, by Players

Chapter 6: Global Market Size by Regions

Chapter 7: Global Market Segment by Application

Chapter 8: Global Down Syndrome Industry Segment by Type

Chapter 9: Market Chain, Sourcing Strategy, and Downstream Buyers

Chapter 10: Strategies and key policies by Distributors/Suppliers/Traders

Chapter 11: Key Marketing Strategy Analysis, by Market Vendors

Chapter 12: Market Effect Factors Analysis

Chapter 13: Global Down Syndrome market Size Forecast (2023-2031).

Continue....

Reasons to Buy This Report

(A) The research provides valuable insights for top administration, policymakers, professionals, product advancements, sales managers, and stakeholders in the market. It helps them make informed decisions and strategize effectively.

(B) The report offers comprehensive analysis of Down Syndrome market revenues on a global, regional, and country level, projecting trends until 2031. This data allows companies to assess their market share, identify growth opportunities, and explore new markets.

(C) The research includes segmentation of the Down Syndrome market based on types, applications, technologies, and end-uses. This segmentation enables leaders to plan their products and allocate resources based on the expected growth rates of each segment.

(D) Analysis of the Down Syndrome market benefits investors by providing insights into market scope, position, key drivers, challenges, restraints, expansion opportunities, and potential threats. This information helps them make informed investment decisions.

(E) The report offers a detailed analysis of competitors, their key strategies, and market positioning. This knowledge allows businesses to better understand the competition and plan their own strategies accordingly.

(F) The study helps evaluate Down Syndrome business predictions by region, key countries, and top companies, providing valuable information for investment planning and decision-making.

Access Full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.Com/industry-verticals/sample-request?Report_id=Pol578

About Report Ocean:

Report Ocean is a renowned provider of market research reports, offering high-quality insights to clients in various industries. Their goal is to assist clients in achieving their top line and bottom line objectives, thereby enhancing their market share in today's competitive environment. As a trusted source for innovative market research reports, Report Ocean serves as a comprehensive solution for individuals, organizations, and industries seeking valuable market intelligence.

Contact Information:

Email:sales@reportocean.Com

Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, United States

Telephone: +1 888 212 3539 (US - Toll-Free)

For more information and to explore their offerings, visit their website at:https://www.Reportocean.Com/

COMTEX_437823396/2796/2023-08-04T06:52:42

© 2023 Benzinga.Com. Benzinga does not provide investment advice. All rights reserved.


Patau's Syndrome

Patau's syndrome is a serious, rare genetic disorder caused by having an additional copy of chromosome 13 in some or all of the body's cells. It's also called trisomy 13.

Each cell normally contains 23 pairs of chromosomes, which carry the genes you inherit from your parents. 

But a baby with Patau's syndrome has 3 copies of chromosome 13, instead of 2.

This severely disrupts normal development and, in many cases, results in miscarriage, stillbirth or the baby dying shortly after birth.

Babies with Patau's syndrome grow slowly in the womb and have a low birth weight, along with a number of other serious medical problems.

Patau's syndrome affects about 1 in every 4,000 births. The risk of having a baby with the syndrome increases with the mother's age.

More than 9 out of 10 children born with Patau's syndrome die during the first year.

Symptoms and features

Babies with Patau's syndrome can have a wide range of health problems.

Their growth in the womb is often restricted, resulting in a low birth weight, and 8 out of 10 will be born with severe heart defects.

The brain often does not divide into 2 halves. This is known as holoprosencephaly.

When this happens, it can affect facial features and cause defects such as:

  • cleft lip and palate
  • an abnormally small eye or eyes (microphthalmia)
  • absence of 1 or both eyes (anophthalmia)
  • Other abnormalities of the face and head include:

  • smaller than normal head size (microcephaly)
  • ear malformations and deafness
  • Patau's syndrome can also cause other problems, such as:

  • an abdominal wall defect where the abdomen does not develop fully in the womb, resulting in the intestines being outside the body, covered only by a membrane – this is known as an exomphalos or omphalocoele
  • abnormal cysts in the kidneys
  • There may also be abnormalities of the hands and feet, such as extra fingers or toes (polydactyly) and a rounded bottom to the feet, known as rocker-bottom feet.

    Causes of Patau's syndrome

    Patau's syndrome happens by chance and is not caused by anything the parents have done.

    Most cases do not run in families (they're not inherited). They happen randomly during conception, when the sperm and egg combine and the foetus starts to develop.

    There's an error when the cells divide, resulting in an additional copy, or part of a copy, of chromosome 13, which severely affects the baby's development in the womb.

    In many cases, the baby dies before reaching full term (miscarriage) or is dead at birth (stillbirth).

    In most cases of Patau's syndrome, a baby has a whole extra copy of chromosome number 13 in their body's cells. This is sometimes known as trisomy 13 or simple trisomy 13.

    In some cases of Patau's syndrome, genetic material is rearranged between chromosome 13 and another chromosome. This is called a chromosomal translocation. Patau's syndrome that arises because of this can be inherited.

    Sometimes only some cells have the extra copy of chromosome 13. This is known as trisomy 13 mosaicism. Occasionally, only part of 1 chromosome 13 is extra (partial trisomy 13).

    The symptoms and features of both mosaicism and partial trisomy tend to be less severe than in simple trisomy 13, resulting in more babies living longer.

    Genetic Alliance UK has more information about chromosome disorders

    Screening for Patau's syndrome

    You'll be offered a screening test for Patau's syndrome, as well as Down's syndrome (trisomy 21) and Edwards' syndrome (trisomy 18), from 10 to 14 weeks of pregnancy.

    The test assesses your chances of having a baby with these syndromes.

    The screening test offered at 10 to 14 weeks of pregnancy is called the combined test because it involves a blood test and an ultrasound scan.

    If the screening tests show you have a higher chance of having a baby with Patau's syndrome, you'll be offered a second screening test called non-invasive prenatal testing (NIPT).

    This is a blood test that can give you a more accurate screening result and help you to decide whether to have a diagnostic test or not. It's available free on the NHS.

    A diagnostic test will check the chromosomes in a sample of cells taken from your baby and helps to find out for certain if they have Patau's syndrome.

    Two techniques can be used to obtain the cell sample: amniocentesis or chorionic villus sampling (CVS). 

    These are invasive tests to remove a sample of tissue or fluid so it can be tested for the presence of the extra copy of chromosome 13.

    If you're not able to have the combined screening test, you'll be offered a scan that looks for physical abnormalities, including those found in Patau's syndrome.

    This is sometimes called the mid-pregnancy scan and is carried out when you're between 18 and 21 weeks pregnant.

    Find out more about screening tests for Down's syndrome, Edwards' syndrome and Patau's syndrome

    Treating and managing Patau's syndrome

    There's no specific treatment for Patau's syndrome. As a result of the severe health problems a newborn baby with the syndrome will have, doctors usually focus on minimising discomfort and ensuring the baby is able to feed.

    For the small number of babies with Patau's syndrome who survive beyond the first few days of life, their care will depend on their specific symptoms and needs.

    If your baby is diagnosed with Patau's syndrome, either before birth or shortly afterwards, you'll be offered counselling and support.

    Genetic testing for parents

    Both parents will need to have their chromosomes analysed if their baby is affected by Patau's syndrome caused by a chromosomal translocation.

    Genetic testing is carried out to help parents plan for future pregnancies, rather than as part of the decision-making process for the current pregnancy.

    The test results will allow a more accurate assessment to be made of the likelihood of the syndrome affecting future pregnancies.

    Other family members may also be affected and should be tested.

    Find out more about genetic and genomic testing

    Information about your child

    If your child has Patau's syndrome, your clinical team will pass information about him or her on to the National Congenital Anomaly and Rare Disease Registration Service (NCARDRS).

    This helps scientists look for better ways to prevent and treat this condition. You can opt out of the register at any time.

    Find out more about the National Congenital Anomaly and Rare Disease Registration Service on GOV.UK

    Further information and support

    These organisations are useful further sources of information about Patau's syndrome.

    They can also provide advice and support:

    Page last reviewed: 18 July 2023Next review due: 18 July 2026






    Comments